Drugs Made In America Acquisition (DMAA) Accumulated Expenses (2024 - 2025)
Drugs Made In America Acquisition (DMAA) reported Accumulated Expenses of $153988.0 for Q4 2025, up 174.66% on a YoY basis from $56065.0 in Q4 2024, and little changed quarter-over-quarter from $153988.0 in Q3 2025.
Drugs Made In America Acquisition (DMAA) Accumulated Expenses (2024 - 2025) Analysis & Trends
Drugs Made In America Acquisition has reported Accumulated Expenses for 2 years, with the latest figure at $153988.0 in Q4 2025.
- For the quarter ending Q4 2025, Accumulated Expenses rose 174.66% year-over-year to $153988.0; the trailing twelve-month figure through Dec 2025 stood at $153988.0 (up 174.66% YoY), and the FY2025 full-year result was $153988.0, up 174.66% from the prior year.
- Accumulated Expenses for Q4 2025 stood at $153988.0, roughly flat from $153988.0 in the prior quarter.
- The five-year high for Accumulated Expenses was $153988.0 in Q1 2025, with the low at $56065.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | EQV Ventures Acquisition | 477.69 Mn | 477.69 Mn | - |
| 2 | Berto Acquisition | 312.46 Mn | 312.46 Mn | - |
| 3 | Centurion Acquisition | 311.65 Mn | 311.65 Mn | - |
| 4 | GP-Act III Acquisition | 311.36 Mn | 311.36 Mn | - |
| 5 | Churchill Capital Corp IX | 310.79 Mn | 310.79 Mn | - |
| 6 | WEN Acquisition | 309.15 Mn | 309.15 Mn | - |
| 7 | Bold Eagle Acquisition | 275.54 Mn | 275.54 Mn | - |
| 8 | Soulpower Acquisition | 264.91 Mn | 264.91 Mn | - |
| 9 | BTC Development | 262.16 Mn | 262.16 Mn | - |
| 10 | Drugs Made In America Acquisition | 223.11 Mn | 223.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 153,988.00 |
| Sep 30, 2025 | 153,988.00 |
| Jun 30, 2025 | 147,453.00 |
| Mar 31, 2025 | 153,988.00 |
| Dec 31, 2024 | 56,065.00 |